Patients with a history of a different malignancy are excluded, unless the disease has not progressed for >=  years
Patients with a history of any malignancy are ineligible
History of prior malignancy, except (Criteria a through f):
History of other malignancy within  years prior to screening
History of another malignancy within  years of the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
Has a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for  years.
Prior other malignancy within  years (except for in situ disease, which is permissible).
Patients who have a history of another primary malignancy that has been diagnosed or required therapy within  years before randomization.
History of another malignancy except for:
Active second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed >  months prior and/or bone marrow transplant >  years prior
Other malignancy requiring treatment in the prior  years
History of malignancy other than NSCLC within  years prior to screening
Have a history of another primary malignancy, with the exception of:
Has history of other active malignancy within  years prior to enrollment, except:
Patients must not have received treatment for another malignancy within  years of enrollment
Prior malignancy or therapy for a malignancy within  years
Participants with presence of other active malignancy within  years of study entry; participants with history of prior malignancy treated with curative intent and achieved CR within  years are eligible.
Other malignancy within  years prior to screening, with some exceptions
Active malignancy besides NSCLC within  years prior to screening.
No prior history of malignancy within  years, unless cured of a skin cancer or a stage I-III solid tumor; no prior hematologic malignancy within  years
Subjects with a history of prior malignancy with the exception of carcinoma in situ of the cervix or other malignancy diagnosed >  years ago that has undergone potentially curative therapy with no evidence of disease for the last >=  years and that is deemed by the investigator to be at a low risk of recurrence
History of malignancy other than their lymphoma with the exception of:
Has a history of another malignancy.
Patients with prior malignancy and treated with no evidence of active disease, and more than  years from initial diagnosis are eligible
History of other malignancy within the last  years (with exceptions).
Participants with a history of other malignancy within  years prior to screening
A history of other malignancy =<  years previous which would preclude endocrine treatment of their cancer
No active prior malignancy within  years of registration (with the exception of non-melanoma skin cancer, in-situ cancers, or Rai stage  chronic lymphocytic leukemia [CLL]); if patient is disease free from a prior malignancy between - years, special consideration can be requested; in these cases, if the risk of recurrence at  years is less than %, and in the opinion of the investigator the prior malignancy will not affect the patient's outcome in light of newly diagnosed pancreatic cancer, the patient may be eligible; this will require principal investigator (PI) review and approval on a case by case basis, and approval will be documented in the medical record; all patients who have been disease free from a prior malignancy for at least  years will be eligible
History of another primary invasive malignancy that has not been definitively treated or in remission for at least  years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses); if patients have another malignancy that was treated within the last  years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within  years is less than %, as determined by an expert in that particular malignancy at MD Anderson Cancer Center and after consultation with the principal investigator
Previous chemotherapy for any malignancy, if given within three years of registration
Other malignancy within five years, except the following may be eligible:
Patients with a history of any other malignancy, except patients with a secondary brain tumor if the patients first malignancy has been in remission for at least  years from the end of treatment
No chemotherapy for a malignancy in the last  years
Concurrent malignancy or history of other malignancy within the last five years except as noted above
History of a non-lymphoid malignancy except for protocol allowed exceptions
History of malignancy;
History of another primary malignancy
History of another primary malignancy that has not been in remission for at least  years.
An active second malignancy or history of another malignancy within the last  years, with exceptions.
Malignancy within the last  years
History of concurrent malignancy requiring active therapy or prior history of another malignancy within  years.
Patients with a history of another malignancy within  years of study enrollment
Individuals with a history of a previous malignancy are ineligible; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than  years prior to registration may be enrolled
History of other malignancy within  years prior to screening
Presence of malignancy other than the study indication under this trial within  years of study enrollment
History of prior malignancy
History of prior malignancy, with the exception of the following:
Patients who have a history of any hematopoietic malignancy
History of prior malignancy except:
History of other malignancy within the last  years
Have a concurrent malignancy or had another malignancy within  years (? years) of study enrollment.
Known history of another primary malignancy that has not been in remission for ? years
Evidence within the last  years of another malignancy which required systemic treatment
History of any other malignancy other than skin cancer, or low grade bladder cancer which has been completely resected, within the previous  years. Patients that have had curative treatment of a previous malignancy and no recurrence of that malignancy within the past  years will be allowed.
Have prior malignancy active within the previous  years;
Subject has a history of a malignancy (other than the disease under treatment in the study) within  years before first study treatment administration
There is any evidence of other malignancy being present within the last three years;
Patient has a history of hematological malignancy within the last  years prior to study entry
History of another malignancy within  years
Other malignancy within the last  years
Patients with another primary malignancy that has not been in remission for at least  years.
History of any other malignancy
History of another primary malignancy
Other malignancy within  years prior to Day  of the study, except for those treated with surgical intervention only.
Patients with a history of any other malignancy will not be eligible
History of hematologic or primary solid tumor malignancy, unless no evidence of that disease for  years
History of other primary malignancy (including myeloid malignancy, e.g., myelodysplastic syndrome), unless
Prior history of metastatic malignancy
Other malignancy within five years, except that the following may be eligible:
Actively being treated for other malignancy; if there is a history of prior malignancy, patient must not be receiving other specific treatment for their cancer
Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for  years
Presence of malignancy other than the study indication under this trial within  years of study enrollment
History of metastatic malignancy in the preceding  years
Participants with history of another primary malignancy not in remission for at least  years
History of metastatic malignancy in the preceding  years
Diagnosis of another malignancy within  years before first dose of study treatment.
History of prior malignancy within  years; patients who are considered no evidence of disease (NED) from a malignancy may be considered on a case by case basis
Other malignancy within the last  years (few exceptions apply);
History of another primary malignancy that has not been in remission for at least  years
History of other active malignancy within the prior  years
Has a history of a malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for  years
Any history of another metastatic malignancy
Presence of any other malignancy or history of prior malignancy within  years of study entry; within  years, patients treated for stage I or II cancers are eligible provided they have a life expectancy >  years in relation to this prior malignancy; the -year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer
the malignancy has been in remission without treatment for ?  years prior to enrollment, or
History of another primary malignancy that has not been in remission for  years
History of another malignancy within  years prior to starting study treatment
Prior history of other malignancy except:
History (within  years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small (<% in  years in the judgment of the investigator).
Patients with a completely treated prior malignancy with no evidence of disease for ? years are eligible
Active malignancy other than SCLC within the previous  years
History of another malignancy, some exceptions may apply.
History of malignancy other than ALL within  years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of disease
No history of any hematopoietic malignancy
History of another malignancy within the previous  years;
History of another primary malignancy that has not been in remission for at least  years
History of any hematopoietic malignancy
History of a primary bone malignancy involving the lumbar spine
Has history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least  years prior to randomization
Patients may have a history of other prior malignancy
History of previous systemic chemotherapy unless given curatively for other malignancy now >  years without evidence of recurrence
Participants has a history of hematological malignancy within the last  years prior to study entry
Pathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within  years of registration; if the original histologic proof of malignancy is greater than  years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)
Another malignancy within  years
Non-hematologic malignancy within prior three () years.
Has history of other active malignancy within  years prior to enrollment, except:
History of malignancy (other than the disease that required the HCT) within  years prior to screening.
Has a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for  years
Women with a history of a prior malignancy
History of gynecologic malignancy that is estrogen dependent
